HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

[Olanzapine induced rhabdomyolysis and serum creatine kinase increase]

AbstractINTRODUCTION: "Atypical" antipsychotics tend to replace traditional antipsychotics as first line therapy for psychotic disorders, due to their better side-effect profile with fewer extrapyramidal manifestations, allowing a better observance. Nevertheless, second-generation antipsychotics may also lead to adverse events such as metabolic disorders, agranulocytosis or muscle damage. Cases of rhabdomyolysis (aside neuroleptic malignant syndrome) have been reported in patients receiving olanzapine (Zyprexa). METHODS: We reviewed the cases of olanzapine induced rhabdomyolysis reported to the French national database of drug adverse events and retrieved additional cases published in the medical literature. RESULTS: We collected 13 cases from the French pharmacovigilance database and eight additional cases from the literature. Seventeen patients needed hospitalization. Creatine kinase (CK) rate ranged between 413 and 34,500 UI/L. Outcome was favorable in 85% of the cases (17 out of 20 cases) after discontinuation of olanzapine. CONCLUSION: Although rhabdomyolysis is a rare side effect (< 1%) of olanzapine, this adverse event should be evoked when a patient with olanzapine presents with muscle pain, unexplained fatigue or weakness. Prompt dosage of CK should be performed. However, it remains uncertain whether a mild and asymptomatic muscle enzyme increase without any metabolic disorder requires the discontinuation of olanzapine therapy.
AuthorsS Ribeyron, C Guy, M Koenig, P Cathébras (Affiliation: Département de médecine générale, faculté de médecine Jacques-Lisfranc, université Jean-Monnet, 42023 Saint-Etienne cedex 2, France.)
JournalLa Revue de médecine interne / fondée ... par la Société nationale francaise de médecine interne (Rev Med Interne) Vol. 30 Issue 6 Pg. 477-85 (Jun 2009) ISSN: 0248-8663 [Print] France
Vernacular TitleRhabdomyolyse et élévation des enzymes musculaires sous olanzapine.
PMID19307047 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Antipsychotic Agents
  • Benzodiazepines
  • olanzapine
  • Creatine Kinase
Topics
  • Adolescent
  • Adult
  • Adverse Drug Reaction Reporting Systems
  • Aged
  • Aged, 80 and over
  • Antipsychotic Agents (adverse effects)
  • Benzodiazepines (adverse effects)
  • Creatine Kinase (blood)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Rhabdomyolysis (chemically induced)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD